0001193125-18-037317.txt : 20180209 0001193125-18-037317.hdr.sgml : 20180209 20180209102411 ACCESSION NUMBER: 0001193125-18-037317 CONFORMED SUBMISSION TYPE: 15-12B PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20180209 DATE AS OF CHANGE: 20180209 EFFECTIVENESS DATE: 20180209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REPROS THERAPEUTICS INC. CENTRAL INDEX KEY: 0000897075 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 760233274 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12B SEC ACT: 1934 Act SEC FILE NUMBER: 001-15281 FILM NUMBER: 18589195 BUSINESS ADDRESS: STREET 1: 2408 TIMBERLOCH PL STREET 2: SUITE B-7 CITY: WOODLANDS STATE: TX ZIP: 77380 BUSINESS PHONE: 2817193400 MAIL ADDRESS: STREET 1: 2408 TIMBERLOCH PLACE B-7 CITY: THE WOODLANDS STATE: TX ZIP: 77380 FORMER COMPANY: FORMER CONFORMED NAME: REPROS THERAPEUTICS INC DATE OF NAME CHANGE: 20060503 FORMER COMPANY: FORMER CONFORMED NAME: ZONAGEN INC DATE OF NAME CHANGE: 19930208 15-12B 1 d497887d1512b.htm 15-12B 15-12B

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-15281

 

 

REPROS THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

 

2408 Timberloch Place, Suite B-7

The Woodlands, Texas 77380

(281) 719-3400

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, $0.001 par value

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)   ☒
Rule 12g-4(a)(2)   ☐
Rule 12h-3(b)(1)(i)   ☒
Rule 12h-3(b)(1)(ii)   ☐
Rule 15d-6   ☐

Approximate number of holders of record as of the certification or notice date: One*

 

* On January 31, 2018 pursuant to the Agreement and Plan of Merger, dated as of December 11, 2017, by and among Allergan Sales, LLC (“Parent”), a Delaware limited liability company and direct wholly owned subsidiary of Allergan plc, an Irish public limited company (“Allergan”), Celestial Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Allergan (“Purchaser”) and Repros Therapeutics Inc., a Delaware corporation (“Repros”), Purchaser merged with and into Repros, with Repros being the surviving entity (the “Merger”). As a result of the Merger, Repros became an indirect wholly owned subsidiary of Allergan.

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Repros Therapeutics Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

    REPROS THERAPEUTICS INC.
Date: February 9, 2018     By:   /s/ A. ROBERT D. BAILEY
      A. Robert D. Bailey
      President, Director